PET-adapted salvage therapy in Hodgkin's lymphoma
Mené sur 46 patients atteints d'un lymphome hodgkinien récidivant ou réfractaire, cet essai de phase II évalue l'efficacité et la toxicité d'un traitement de sauvetage comprenant un premier cycle de brentuximab vedotin puis, après l'observation d'anomalies persistantes à l'aide d'une tomographie par émission de positrons, une chimiothérapie combinant ifosfamide, carboplatine et étoposide
More than three decades after the discovery of the CD30 molecule, targeted therapy is becoming a reality for Hodgkin's lymphoma, paralleling therapeutic trends in other cancers such as breast cancer and non-Hodgkin lymphoma. Brentuximab vedotin is an antibody–drug conjugate that combines the anti-CD30 antibody with a cytotoxic tubulin-disrupting agent. Brentuximab vedotin has substantial activity and low toxicity in patients with refractory or chemoinsensitive Hodgkin's lymphoma. Clinical studies assessing the use of brentuximab vedotin before or after allogeneic transplantation and in early-stage disease, with or without radiation therapy, are in progress.
The Lancet Oncology , commentaire, 2014